CG Oncology (CGON) Competitors

CG Oncology logo
$79.47 -2.43 (-2.97%)
Closing price 04:00 PM Eastern
Extended Trading
$79.50 +0.03 (+0.04%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CGON vs. ROIV, INSM, UTHR, INCY, and BNTX

Should you buy CG Oncology stock or one of its competitors? CG Oncology's main competitors and comparable companies include Roivant Sciences (ROIV), Insmed (INSM), United Therapeutics (UTHR), Incyte (INCY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CG Oncology compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Roivant Sciences has a net margin of -838.21% compared to CG Oncology's net margin of -3,851.09%. Roivant Sciences' return on equity of -22.03% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-838.21% -22.03% -20.55%
CG Oncology -3,851.09%-24.58%-23.40%

Roivant Sciences has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Roivant Sciences presently has a consensus target price of $46.82, indicating a potential upside of 20.17%. CG Oncology has a consensus target price of $102.22, indicating a potential upside of 24.81%. Given CG Oncology's higher probable upside, analysts plainly believe CG Oncology is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

CG Oncology has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$8.26M3,417.54-$299.77M-$0.63N/A
CG Oncology$4.04M1,810.72-$160.99M-$2.76N/A

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, CG Oncology had 31 more articles in the media than Roivant Sciences. MarketBeat recorded 43 mentions for CG Oncology and 12 mentions for Roivant Sciences. CG Oncology's average media sentiment score of 0.70 beat Roivant Sciences' score of 0.41 indicating that CG Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CG Oncology
15 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

Roivant Sciences beats CG Oncology on 12 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Insmed?

Insmed (NASDAQ:INSM) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

26.6% of CG Oncology shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CG Oncology has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42M52.26-$1.28B-$2.82N/A
CG Oncology$4.04M1,810.72-$160.99M-$2.76N/A

Insmed presently has a consensus target price of $196.52, indicating a potential upside of 36.04%. CG Oncology has a consensus target price of $102.22, indicating a potential upside of 24.81%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts clearly believe Insmed is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

Insmed has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, CG Oncology had 26 more articles in the media than Insmed. MarketBeat recorded 43 mentions for CG Oncology and 17 mentions for Insmed. Insmed's average media sentiment score of 0.72 beat CG Oncology's score of 0.70 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
6 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CG Oncology
15 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Insmed has a net margin of -39.85% compared to CG Oncology's net margin of -3,851.09%. CG Oncology's return on equity of -24.58% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-39.85% -96.38% -32.55%
CG Oncology -3,851.09%-24.58%-23.40%

Summary

CG Oncology beats Insmed on 9 of the 17 factors compared between the two stocks.

How does CG Oncology compare to United Therapeutics?

CG Oncology (NASDAQ:CGON) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CG Oncology$4.04M1,810.72-$160.99M-$2.76N/A
United Therapeutics$3.18B7.48$1.33B$26.5021.10

CG Oncology currently has a consensus target price of $102.22, suggesting a potential upside of 24.81%. United Therapeutics has a consensus target price of $676.40, suggesting a potential upside of 20.98%. Given CG Oncology's higher probable upside, research analysts plainly believe CG Oncology is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

CG Oncology has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, CG Oncology had 27 more articles in the media than United Therapeutics. MarketBeat recorded 42 mentions for CG Oncology and 15 mentions for United Therapeutics. CG Oncology's average media sentiment score of 0.70 beat United Therapeutics' score of 0.44 indicating that CG Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CG Oncology
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
United Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

United Therapeutics has a net margin of 38.61% compared to CG Oncology's net margin of -3,851.09%. United Therapeutics' return on equity of 19.18% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
CG Oncology-3,851.09% -24.58% -23.40%
United Therapeutics 38.61%19.18%17.07%

Summary

United Therapeutics beats CG Oncology on 12 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Incyte?

CG Oncology (NASDAQ:CGON) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

CG Oncology presently has a consensus price target of $102.22, indicating a potential upside of 24.81%. Incyte has a consensus price target of $133.86, indicating a potential upside of 15.52%. Given CG Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe CG Oncology is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44

Incyte has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CG Oncology$4.04M1,810.72-$160.99M-$2.76N/A
Incyte$5.14B4.59$1.29B$1.8861.63

In the previous week, CG Oncology had 21 more articles in the media than Incyte. MarketBeat recorded 42 mentions for CG Oncology and 21 mentions for Incyte. CG Oncology's average media sentiment score of 0.70 beat Incyte's score of 0.43 indicating that CG Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CG Oncology
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Incyte
6 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Incyte has a net margin of 6.71% compared to CG Oncology's net margin of -3,851.09%. Incyte's return on equity of 7.92% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
CG Oncology-3,851.09% -24.58% -23.40%
Incyte 6.71%7.92%6.12%

CG Oncology has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Incyte has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Summary

Incyte beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does CG Oncology compare to BioNTech?

BioNTech (NASDAQ:BNTX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioNTech has a net margin of -61.39% compared to CG Oncology's net margin of -3,851.09%. BioNTech's return on equity of -4.51% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNTech-61.39% -4.51% -3.96%
CG Oncology -3,851.09%-24.58%-23.40%

BioNTech currently has a consensus price target of $120.44, suggesting a potential upside of 48.02%. CG Oncology has a consensus price target of $102.22, suggesting a potential upside of 24.81%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

BioNTech has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

CG Oncology has lower revenue, but higher earnings than BioNTech. CG Oncology is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$3.25B6.34-$1.29B-$6.85N/A
CG Oncology$4.04M1,810.72-$160.99M-$2.76N/A

In the previous week, CG Oncology had 38 more articles in the media than BioNTech. MarketBeat recorded 42 mentions for CG Oncology and 4 mentions for BioNTech. BioNTech's average media sentiment score of 0.88 beat CG Oncology's score of 0.70 indicating that BioNTech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNTech
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CG Oncology
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

BioNTech beats CG Oncology on 12 of the 17 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGON vs. The Competition

MetricCG OncologyBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.10B$3.92B$7.42B$10.86B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-28.7923.5332.4528.84
Price / Sales1,757.0015.598.085.38
Price / CashN/A22.6520.7221.66
Price / Book7.164.124.313.50
Net Income-$160.99M-$24.03M$3.51B$394.12M
7 Day Performance6.81%-9.57%-7.89%-8.87%
1 Month Performance28.32%-13.67%-10.43%-11.97%
1 Year Performance95.21%-6.29%-2.77%-9.56%

CG Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGON
CG Oncology
3.4131 of 5 stars
$79.47
-3.0%
$102.22
+28.6%
+92.3%$7.10B$4.04MN/A142
ROIV
Roivant Sciences
2.3603 of 5 stars
$38.71
+0.3%
$46.82
+20.9%
+91.5%$27.98B$8.26MN/A721
INSM
Insmed
3.1442 of 5 stars
$121.86
-0.8%
$196.52
+61.3%
-29.0%$26.96B$606.42MN/A1,664
UTHR
United Therapeutics
4.6909 of 5 stars
$584.10
-0.6%
$676.40
+15.8%
+17.3%$25.04B$3.18B22.181,400
INCY
Incyte
3.2964 of 5 stars
$119.09
-1.0%
$132.86
+11.6%
+14.4%$24.51B$5.14B56.732,844

Related Companies and Tools


This page (NASDAQ:CGON) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners